Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

27 Jul 2021

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

A new class of drugs that inhibits a "master switch" involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai.

22 Jun 2021

Wistar researchers discover new enzymatic function of the Epstein-Barr Virus protein

Researchers at The Wistar Institute have discovered a new enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, a critical factor in EBV's ability to transform human cells and cause cancer.

27 Jan 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed at?

17 Dec 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Study explores link between personal use of hair dyes and cancer risk

Studies have indicated that people who dye their hair regularly may have a higher risk of cancer, especially bladder cancer and breast cancer.

3 Sep 2020

FDA provides update on adverse events associated with breast implants

Today, the U.S. Food and Drug Administration is providing an update on adverse events reported to the Agency related to breast implants, including breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and systemic signs and symptoms referred to by patients as breast implant illness (BII), which some patients report after receiving breast implants.

20 Aug 2020

New cancer vaccine shows promising signs in preclinical studies

Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.

9 Jul 2020

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop TYVYT® (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, in rare cancers in the U. S...

19 May 2020

People with a cancer history have increased risk of developing atrial fibrillation

People with a history of cancer have an over two-fold risk of developing atrial fibrillation (AFib), the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

18 Mar 2020

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia, with no major toxicities observed.

6 Feb 2020

UAB seminar on the extraordinary science of the immune system

"The human immune system makes my head explode," Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. "This is by far the hardest subject I have ever had to explore."

15 Dec 2019

Young patients with IBD have increased risk of severe viral infections

Young patients with inflammatory bowel disease are five times more likely than the general population to develop viral infections that can lead to hospitalization or permanent organ damage, a new study published in the UEG Journal has found.

5 Dec 2019

Eisai transfers rights to Royalty Pharma relating to net sales of EZH2 inhibitor outside of Japan

Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.

5 Nov 2019

Molecular mechanisms involved in Pixantrone's interactions with cancer DNA discovered

Recently, a drug named Pixantrone (PIX) was developed, which is far less damaging to the heart than previous, less advanced compounds. PIX is now used to treat cancers including non-Hodgkin's lymphoma and leukaemia, but a detailed knowledge of the molecular processes it uses to destroy cancer cells has been lacking so far.

28 Oct 2019

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of sites across the U.S. are involved in this study, which is done on an outpatient basis.

25 Oct 2019

Patients with non-Hodgkin's lymphoma may benefit from radiation, experience reduced side effects

Treating non-Hodgkin's lymphoma patients with radiation therapy as an additional treatment while they wait for their CAR T cells to be manufactured may reduce the risk of CAR T therapy side effects once it is administered, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania.

18 Sep 2019

Innovative technology could help treat cancer more selectively and effectively

Treating cancer more selectively and more effectively - this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and the Ludwig-Maximilians-Universität München.

9 Aug 2019

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Wistar researchers discover new enzymatic function of the Epstein-Barr Virus protein

MDC researchers develop a potent weapon against lymphomas

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Study explores link between personal use of hair dyes and cancer risk

FDA provides update on adverse events associated with breast implants

New cancer vaccine shows promising signs in preclinical studies

Innovent Biologics and MD Anderson to develop sintilimab injection for rare cancers

People with a cancer history have increased risk of developing atrial fibrillation

CD19 CAR NK cell therapy clinical trial shows encouraging results for hematologic cancers

UAB seminar on the extraordinary science of the immune system

Young patients with IBD have increased risk of severe viral infections

Eisai transfers rights to Royalty Pharma relating to net sales of EZH2 inhibitor outside of Japan

Molecular mechanisms involved in Pixantrone's interactions with cancer DNA discovered

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Patients with non-Hodgkin's lymphoma may benefit from radiation, experience reduced side effects

Innovative technology could help treat cancer more selectively and effectively

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in